Clinical Trials Browser

Not yet recruiting × INDUSTRY × Genitourinary × Clear all

NCT07480356 2026-03-18

ADVANCED-3

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT07475806 2026-03-17

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Not yet recruiting

Muscle-invasive Bladder Cancer

NCT07419841 2026-03-16

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Phase 1 Not yet recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Endometrial Neoplasms

NCT07468851 2026-03-13

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Phase 1/2 Not yet recruiting

High-risk Non-muscle-invasive Bladder Cancer

NCT07457164 2026-03-12

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

Phase 2 Not yet recruiting

Urogenital Diseases, Prostatic Diseases

NCT07468396 2026-03-12

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT07468708 2026-03-12

The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

Phase EARLY_PHASE1 Not yet recruiting

Prostatic Neoplasms

NCT07464145 2026-03-11

RESCUE

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT07454603 2026-03-06

PROSTest_STRAT

Not yet recruiting

Disease, Prostatic Neoplasms

NCT07455058 2026-03-06

VAPOR-LTR

Not yet recruiting

Prostatic Neoplasms

NCT07450599 2026-03-05

CHINANEO

Phase 2 Not yet recruiting

High-Risk Localized Prostate Cancer

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07419295 2026-02-19

TroFuse-031

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT07421700 2026-02-19

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07412275 2026-02-17

MILA

Phase NA Not yet recruiting

Localised Prostate Cancer

NCT07405164 2026-02-12

MK-6482-043

Phase 3 Not yet recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07407283 2026-02-12

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07386847 2026-02-04

A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer

Not yet recruiting

Carcinoma, Transitional Cell

NCT07344779 2026-01-26

ROAD

Not yet recruiting

Prostatic Neoplasms

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Phase 3 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Phase 1/2 Not yet recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07336446 2026-01-13

ANDROMEDA

Phase 1/2 Not yet recruiting

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07310355 2025-12-30

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07144319 2025-12-26

ENAiBLE

Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07290998 2025-12-18

Treatment of Locally Recurrent Prostate Cancer

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07252661 2025-11-28

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Phase 1 Not yet recruiting

DermatologicEndocrineGastrointestinalGenitourinaryHead & Neck

Thyroid cancer, medullary, Carcinoma, Renal Cell, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis

NCT06400160 2025-11-25

Clinical Trial of TB511 in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

GastrointestinalGenitourinary

Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms

NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Phase 1 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07246759 2025-11-24

NEUTROFLOW

Not yet recruiting

BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

NCT07231809 2025-11-21

HIVEC

Phase NA Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma

NCT07223372 2025-10-31

TARA

Not yet recruiting

Metastatic Hormonesensitive Prostate Cancer (mHSPC)

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07198633 2025-09-30

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Phase 1/2 Not yet recruiting

Advanced Prostate Cancer

NCT07197580 2025-09-29

LUTEON

Phase 3 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT07177937 2025-09-22

A Study of DXC014 in Patients With Advanced Solid Tumors.

Phase 1 Not yet recruiting

DermatologicGenitourinaryThoracic

Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT07172126 2025-09-15

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

Phase 1/2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06705686 2025-09-05

PHAROS

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT06607783 2025-08-28

PREDICT

Not yet recruiting

Disease, Prostatic Neoplasms

NCT07104110 2025-08-05

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07104617 2025-08-05

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

Phase 1/2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07087158 2025-07-28

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07056439 2025-07-09

Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients

Phase 1/2 Not yet recruiting

PET Imaging in Patients With Prostate Cancer

NCT06194461 2025-06-27

LOCUS

Not yet recruiting

GastrointestinalGenitourinary

Carcinoma, Hepatocellular, Prostatic Neoplasms

NCT06678633 2025-05-29

T-Control® Safety for Cytostatics Management

Phase NA Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06800963 2025-05-16

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06765954 2025-05-06

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT06765902 2025-05-04

Immunotherapy Before and After Surgery

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT06912672 2025-04-08

UMT-UC

Not yet recruiting

Carcinoma, Transitional Cell, Hematuria

NCT06890832 2025-03-24

A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer

Phase 2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer, MCRPC